SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03154242

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Effect of Genetic Polymorphisms on Clinical Outcome of Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients

This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients

NCT03154242 Carcinoma, Non-Small-Cell Lung
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma


Primary Outcomes

Description: It's defined as the time from day 1 of chemotherapy to the day of documented disease progression or death from any cause.

Measure: Progression-free survival (PFS)

Time: From the date of starting the chemotherapy until the date of documented disease progression or date of death from any cause assessed up to 12 months

Time Perspective: Prospective

Other


There are 2 SNPs

SNPs


1 rs1047768

Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients Progression-free survival (PFS).


2 rs751402

Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients Progression-free survival (PFS).



HPO Nodes


HPO: